ELYS Activators
ELYS activators encompass a range of chemical compounds that can enhance the functional activity of ELYS, a protein crucial for nuclear pore complex formation. Microtubule-disrupting agents such as the microtubule-stabilizing agent taxol, perturb microtubule dynamics. This disruption or stabilization of microtubules can trigger a compensatory response in ELYS, leading to an increase in its functional activity to restore or maintain nuclear pore complex formation.
Proteasome inhibitors like epoxomicin, bortezomib, and MG132, along with the protease inhibitor actinonin, inhibit protein degradation mechanisms, leading to protein accumulation within the cell. This increased protein load can necessitate an increase in nuclear pore complex formation, thus enhancing the functional activity of ELYS. Tunicamycin and thapsigargin, inhibitors of N-linked glycosylation and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase respectively, can also increase the demand for nuclear pore complex formation, thereby enhancing ELYS function. Tunicamycin, by inhibiting N-linked glycosylation, can trigger accumulation of glycoproteins. This glycoprotein accumulation increases the need for nuclear pore complexes to facilitate their transport, thus indirectly stimulating ELYS function. On the other hand, thapsigargin, through its inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase, causes disruption in calcium homeostasis. This disruption can necessitate an increase in nuclear pore complex formation to maintain cellular equilibrium, thereby enhancing the functional activity of ELYS.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol is a microtubule-stabilizing agent. Stabilizing microtubules can result in an increased need for nuclear pore formation to maintain cellular function, thereby enhancing ELYS function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a potent proteasome inhibitor. By inhibiting proteasome activity, it can enhance ELYS function by increasing the need for new nuclear pore formation to remove the accumulated proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It can enhance ELYS function by increasing the need for new nuclear pore formation due to the accumulation of proteins in the cell. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a potent proteasome inhibitor. By inhibiting proteasome activity, it can enhance ELYS function by increasing the need for new nuclear pore formation to remove the accumulated proteins. | ||||||
Actinonin | 13434-13-4 | sc-201289 sc-201289B | 5 mg 10 mg | $170.00 $385.00 | 3 | |
Actinonin is a protease inhibitor. By inhibiting protease activity, it can enhance ELYS function by increasing the need for new nuclear pore formation to remove the accumulated proteins. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin is an inhibitor of N-linked glycosylation. By inhibiting N-linked glycosylation, it can enhance ELYS function by increasing the need for new nuclear pore formation to maintain cellular function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase. By inhibiting this ATPase, it can enhance ELYS function by increasing the need for new nuclear pore formation to maintain cellular function. | ||||||